[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
September 8, 1999

Several Classes of New Drugs Emerging for Parkinson Disease

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(10):929-931. doi:10.1001/jama.282.10.929-JMN0908-2-1

Vancouver, BC—New pharmaceutical strategies in the treatment of Parkinson disease (PD) are emerging as basic and clinical research burgeons throughout the neurological community worldwide.

Discoveries made by Viennese investigator Oleh Hornykiewicz, MD, in the 1960s—that depletion of dopamine in the brains of patients with PD could be overcome by giving them levodopa—turned Parkinson disease from one of the least understood and least studied of the neurologic diseases to one of the best understood and best studied in terms of chemical changes in the brain, Donald Calne, MD, director of the Neurodegenerative Disorders Centre at the University of British Columbia, Vancouver, said at a recent meeting.